AU3819497A - Novel parathyroid hormone-related peptide analogs - Google Patents

Novel parathyroid hormone-related peptide analogs

Info

Publication number
AU3819497A
AU3819497A AU38194/97A AU3819497A AU3819497A AU 3819497 A AU3819497 A AU 3819497A AU 38194/97 A AU38194/97 A AU 38194/97A AU 3819497 A AU3819497 A AU 3819497A AU 3819497 A AU3819497 A AU 3819497A
Authority
AU
Australia
Prior art keywords
parathyroid hormone
related peptide
peptide analogs
pth
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38194/97A
Other languages
English (en)
Inventor
Thomas J. Gardella
Harald Juppner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU3819497A publication Critical patent/AU3819497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Spectrometry And Color Measurement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU38194/97A 1996-07-31 1997-07-30 Novel parathyroid hormone-related peptide analogs Abandoned AU3819497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2547196P 1996-07-31 1996-07-31
US60025471 1996-07-31
PCT/US1997/013360 WO1998004591A1 (en) 1996-07-31 1997-07-30 Novel parathyroid hormone-related peptide analogs

Publications (1)

Publication Number Publication Date
AU3819497A true AU3819497A (en) 1998-02-20

Family

ID=21826255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38194/97A Abandoned AU3819497A (en) 1996-07-31 1997-07-30 Novel parathyroid hormone-related peptide analogs

Country Status (8)

Country Link
US (2) US6147186A (enExample)
EP (1) EP0917537B1 (enExample)
JP (2) JP4142743B2 (enExample)
AT (1) ATE304020T1 (enExample)
AU (1) AU3819497A (enExample)
DE (1) DE69734157T2 (enExample)
ES (1) ES2248853T3 (enExample)
WO (1) WO1998004591A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304020T1 (de) * 1996-07-31 2005-09-15 Gen Hospital Corp Parathyroidhormon-verwandthe peptidanaloge
EP1075491B1 (en) 1998-05-05 2008-04-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Pth2 receptor selective compounds
EP1123401A1 (en) * 1998-10-22 2001-08-16 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
AU5877300A (en) 1999-06-15 2001-01-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pth2 and pth1 receptor ligands
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
JP4837888B2 (ja) * 2001-07-23 2011-12-14 ザ ジェネラル ホスピタル コーポレイション コンホメーションが拘束された副甲状腺ホルモン（ｐｔｈ）類似体
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
CA2496618A1 (en) * 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2002951372A0 (en) * 2002-09-13 2002-09-26 St Vincent's Institute Of Medical Research Parathyroid hormone-like polypeptides
WO2004093902A1 (en) * 2003-03-19 2004-11-04 The General Hospital Corporation CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
US7910544B2 (en) * 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
EP1744683B1 (en) * 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US20060068426A1 (en) * 2004-08-20 2006-03-30 Tam James P Cyclic peptides and antibodies thereof
WO2007133580A2 (en) * 2006-05-09 2007-11-22 Zelos Therapeutics, Inc. Use of pth (1-31) and optionally g-csf for hematopoietic stimulation
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
DK3091075T3 (en) 2007-04-09 2018-07-16 Univ Arkansas FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON
JP5711966B2 (ja) 2007-08-01 2015-05-07 ザ ジェネラル ホスピタル コーポレイション Ｇタンパク質共役受容体および関連組成物を使用するスクリーニング方法
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
PT2459208T (pt) 2009-07-29 2017-01-03 Kai Pharmaceuticals Inc Agentes terapêuticos para redução dos niveis de hormona paratiroideia
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
HK1202086A1 (en) * 2011-11-10 2015-09-18 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
EP3391899B1 (en) 2011-12-14 2020-07-15 The Board of Trustees of the University of Arkansas Delivery of therapeutic agents by a collagen binding protein
EP3272880B1 (en) 2013-03-15 2020-11-25 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
JP7397440B2 (ja) 2017-02-10 2023-12-13 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合薬剤組成物およびその使用方法
JP2021516222A (ja) 2018-03-16 2021-07-01 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921665T2 (de) * 1988-05-09 1995-09-21 Merck & Co Inc Hemmer vom flüssigen kalziumerhöhenden Faktor.
ATE287898T1 (de) * 1991-04-05 2005-02-15 Gen Hospital Corp Parathyroid-hormon-rezeptor und seine kodierende dna
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
CN1070500C (zh) * 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
ATE304020T1 (de) * 1996-07-31 2005-09-15 Gen Hospital Corp Parathyroidhormon-verwandthe peptidanaloge

Also Published As

Publication number Publication date
EP0917537A1 (en) 1999-05-26
WO1998004591A1 (en) 1998-02-05
DE69734157T2 (de) 2006-07-13
EP0917537B1 (en) 2005-09-07
JP4142743B2 (ja) 2008-09-03
ES2248853T3 (es) 2006-03-16
US6362163B1 (en) 2002-03-26
JP2008074868A (ja) 2008-04-03
US6147186A (en) 2000-11-14
JP2001500476A (ja) 2001-01-16
DE69734157D1 (en) 2005-10-13
ATE304020T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
AU3819497A (en) Novel parathyroid hormone-related peptide analogs
HUP9904596A1 (hu) Mellékpajzsmirigy-hormon analógok
IL163066A (en) Ligands for the zcytor17 receptor
EP0293159A3 (en) Parathyroid hormone antagonists with simplified synthetic methodology
MX9604122A (es) Portaherramienta y proceso de corte que usa el portaherramienta.
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
MX9705719A (es) Metodo para la sintesis de analogos de la hormona paratiroidea y del peptido relacionado con la hormona paratioridea.
EP0334244A3 (en) Bradykinin antagonist peptides
EP0475394A3 (en) Rat c-type natriuretic peptide cdna and precursor protein
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
MY127575A (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2001023521A3 (en) Polypeptide derivatives of parathyroid hormone (PTH)
GB9126725D0 (en) Process
EP0339549A3 (en) Tyr-peptide analogs
PT79837A (en) Process for the preparation of 5,11-dihydro-6h-dibenzo<b,e>azepine-6-ones substituted and pharmaceutical compositions therewith
WO1999014345A3 (de) Arzneimittel zur therapie einer manifesten lyme-borreliose
IL138658A0 (en) Chimeric protein
AU2486800A (en) Pth functional domain conjugate peptides, derivatives thereof and novel tetheredligand-receptor molecules
GR950300029T1 (en) Dna encoding a human serotonin receptor (5-ht4b)a nd uses thereof.
GB9726630D0 (en) Kv2.1 Antagonists
ES2140835T3 (es) Preparacion del 4,6-dimetoxi-2-((fenoxicarbonil)amino)-pirimidina.
TWI255812B (en) A process for the preparation of r-(+)-6-carboxamido-3-n-methylamino-1,2,3,4-tetrahydrocarbazole
EP0672679A4 (en) PEPTIDE INHIBITING PHOSPHOLIPASE C.
ES8702876A1 (es) Procedimiento para la obtencion de acido monocloroacetico a partir de acido glicolico
TW197410B (enExample)